New Zealand markets closed
  • NZX 50

    11,296.43
    +118.40 (+1.06%)
     
  • NZD/USD

    0.5999
    +0.0035 (+0.58%)
     
  • NZD/EUR

    0.5667
    +0.0027 (+0.47%)
     
  • ALL ORDS

    7,249.70
    +27.20 (+0.38%)
     
  • ASX 200

    7,048.60
    +23.80 (+0.34%)
     
  • OIL

    90.77
    -0.94 (-1.02%)
     
  • GOLD

    1,864.60
    -14.00 (-0.75%)
     
  • NASDAQ

    14,715.24
    +12.48 (+0.08%)
     
  • FTSE

    7,608.08
    +6.23 (+0.08%)
     
  • Dow Jones

    33,507.50
    -158.84 (-0.47%)
     
  • DAX

    15,386.58
    +63.08 (+0.41%)
     
  • Hang Seng

    17,809.66
    +436.63 (+2.51%)
     
  • NIKKEI 225

    31,857.62
    -14.90 (-0.05%)
     
  • NZD/JPY

    89.5710
    +0.5850 (+0.66%)
     

Looking for Passive Income at a Decent Price? Buy These 2 Stocks

Looking for Passive Income at a Decent Price? Buy These 2 Stocks

Many investors would love to buy passive income stocks with a high dividend yield, a sustainable level of earnings coverage of the dividend, and a cheap valuation. For instance, Zoloft, Xanax, Lyrica, Viagra, and Lipitor are just a few of the older household-name drug brands that Viatris (NASDAQ: VTRS) counts in its portfolio of generic medicines, and while none are new medicines, they're each indispensable to this day. Viatris' forward dividend yield is presently above 5.2%, which is on the high side compared to the market's average yield of around 1.6%.